Výsledky vyhledávání

Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme

Autor: A. Thakerar, S. W. Kirsa, S. W. K. Yip, P. Van Koeverden, Michael Michael, James D Mellor

Publikováno v: Internal Medicine Journal. 42:1224-1229

BACKGROUND: The off-label use of a drug refers to a use outside the terms of its approval by the Therapeutic Goods Administration (TGA). It is also possible to prescribe unlicensed drugs under the TGA's special access scheme. A high rate of off-label

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::54c1f5517df820d66a033fabd1f57c6f
https://doi.org/10.1111/j.1445-5994.2012.02751.x

Zobrazit plný text záznamu

Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme

Autor: J D, Mellor, P, Van Koeverden, S W K, Yip, A, Thakerar, S W, Kirsa, M, Michael

Publikováno v: Internal medicine journal. 42(11)

The off-label use of a drug refers to a use outside the terms of its approval by the Therapeutic Goods Administration (TGA). It is also possible to prescribe unlicensed drugs under the TGA's special access scheme. A high rate of off-label prescribing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9f57b896accf99630dd6f04e1377abc9
https://pubmed.ncbi.nlm.nih.gov/22372936

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání